Results 181 to 190 of about 9,765 (234)

Real-World Treatment Efficacy and Safety Profile of Sofosbuvir- and Velpatasvir-Based HCV Treatment in South Korea: Multicenter Prospective Study. [PDF]

Viruses
Yoon JH, Lee CH, Jo HG, Cho JY, Kim JD, Kim JW, You GR, Cho SB, Choi SK.   +8 more
europepmc   +1 more source

Reinfection and Resistance Associated Substitutions Following a Minimal Monitoring Approach for Hepatitis C Virus Treatment in MINMON Trial. [PDF]

Clin Infect Dis
Han WM, Solomon SS, Smeaton L, Avihingsanon A, Wagner Cardoso S, Li J, Parvangada A, Sulkowski M, Naggie S, Martin R, Mo H, Maiorova E, Wyles D.   +12 more
europepmc   +1 more source

Prevalence of resistance-associated substitutions (RAS) in hepatitis C virus in the Former Soviet Union countries. [PDF]

BMJ Open Gastroenterol
Mustafa A, Davlidova S, Abidi SH, Begimbetova D, Heimer R, Vermund SH, Ali S.   +6 more
europepmc   +1 more source

Mechanisms and Therapeutic Strategies for HCV/HBV-Associated B-Cell Non-Hodgkin's Lymphomas: A Viewpoint. [PDF]

Oncol Res
Carloni G, Rinaldi M.
europepmc   +1 more source

Tracking the evolution of multiple in vitro HCV replicon mutants under protease inhibitor selection pressure by 454 ultra deep sequencing. [PDF]

Claes, Marijke, Fanning, G, Lenz, O, Neyts, Johan, Simmen, K, Van Marck, H, Vandenbroucke, I, Verbinnen, T, Vijgen, L   +8 more
core  

Some of the next articles are maybe not open access.

Related searches:

NS5A Inhibitors

Current Hepatitis Reports, 2012
As a result of rapid advance medicinal chemistry, the time frame 2011–2012 has been an exciting one that has witnessed the release of the first direct acting antiviral agents (DAA). Multiple enzymatic and protein regions of the virus can serve as targets for these new drugs. One of the newest and most promising of these targets is the NS5A protein. The
Christopher O’Brien, Nicholas Agresti
openaire   +1 more source

HCV NS5A replication complex inhibitors

Current Opinion in Pharmacology, 2016
The development of anti-HCV drugs is one of the most successful stories of antiviral therapy. In fact, for the first time in human history we have the potential to eradicate a chronic viral infection using only orally administered direct antiviral agents (DAAs).
Min, Gao, Donald R, O'Boyle, Susan, Roberts   +2 more
openaire   +2 more sources

Discovery of fluorobenzimidazole HCV NS5A inhibitors

Bioorganic & Medicinal Chemistry Letters, 2016
Research toward a next-generation HCV NS5A inhibitor has identified fluorobenzimidazole analogs that demonstrate potent, broad-genotype in vitro activity against HCV genotypes 1-6 replicons as well as HCV NS5A variants that are orders of magnitude less susceptible to inhibition by first-generation NS5A inhibitors in comparison to wild-type replicons ...
John T, Randolph, Charles A, Flentge, Pamela, Donner, Todd W, Rockway, Sachin V, Patel, Lissa, Nelson, Douglas K, Hutchinson, Rubina, Mondal, Neeta, Mistry, Thomas, Reisch, Tatyana, Dekhtyar, Preethi, Krishnan, Tami, Pilot-Matias, Deanne F, Stolarik, David W A, Beno, Rolf, Wagner, Clarence, Maring, Warren M, Kati   +17 more
openaire   +2 more sources

The NS5A Replication Complex Inhibitors: Difference Makers?

Clinics in Liver Disease, 2011
The development and approval of direct-acting antiviral agents looks set to transform the treatment of chronic hepatitis C infection. Among the agents in development are novel compounds that inhibit the function of the NS5A protein: a pleiotropic protein with a complex and essential role in viral replication.
Robert G, Gish, Nicholas A, Meanwell
openaire   +2 more sources

Discovery of potent macrocyclic HCV NS5A inhibitors

Bioorganic & Medicinal Chemistry Letters, 2016
HCV NS5A inhibitors have demonstrated impressive in vitro virologic profiles in HCV replicon assays and robust HCV RNA titer reduction in the clinic making them attractive components for inclusion in an all oral fixed-dose combination (FDC) regimen for the treatment of HCV infection.
Wensheng Yu, Bancha Vibulbhan, Stuart B. Rosenblum, Gregory S. Martin, A. Samuel Vellekoop, Christian L. Holst, Craig A. Coburn, Michael Wong, Oleg Selyutin, Tao Ji, Bin Zhong, Bin Hu, Lei Chen, Michael P. Dwyer, Yueheng Jiang, Anilkumar G. Nair, Ling Tong, Qingbei Zeng, Sony Agrawal, Donna Carr, Laura Rokosz, Rong Liu, Stephanie Curry, Patricia McMonagle, Paul Ingravallo, Fred Lahser, Ernest Asante-Appiah, James Fells, Joseph A. Kozlowski   +28 more
openaire   +2 more sources